4
Changes in Ownership
Ultragenyx Pharmaceutical Inc. Filed Acc 0001209191-22-015830
EVP & Chief Commercial Officer sold 2,713 shares at $66.62 ($180,740)
- EVP & Chief Commercial Officer acquired 14,000 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Harris Erik EVP & Chief Commercial Officer | 2022-03-01 | Sale | −2,713 | $66.62 | $180,740 | 22,317 | D: show line 1 in the form |
| Harris Erik EVP & Chief Commercial Officer | 2022-03-01 | Grant or award | +14,000 | 36,317 | D: show line 2 in the form | ||
| Open-market sales · 2,713 sh · avg $66.62 · $180,740 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Harris Erik EVP & Chief Commercial Officer | 2022-03-01 | Grant or award · Stock Option (Right to Buy) | +24,900 | 24,900 | D: show line 3 in the form |
Loading xslF345X03/doc4.xml…